Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRODIGE 87 FOXTROT II
2023-505214-23-00Phase 3Authorised
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Aug 2023
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised trial of fluorouracil, folinic acid and oxaliplatin in colon cancer (2 arms), sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Primary endpoint: Disease-free survival. Planned start Aug 2023; status: authorised.
02
Drugs
fluorouracilfolinic acidoxaliplatin
03
Conditions
colon cancer
Beyond the preview
Go deeper on 2023-505214-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505214-23-00.